Publication date: Apr 09, 2025
The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
| Concepts | Keywords |
|---|---|
| Coronavirus | 3CL |
| Hours | Protease Inhibitor |
| Liver | S-892216 |
| Outpatient | |
| Pcr |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | coronavirus disease 2019 |
| disease | MESH | infection |
| disease | IDO | symptom |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | IDO | nucleic acid |
| drug | DRUGBANK | Medical air |
| drug | DRUGBANK | Etoperidone |
| drug | DRUGBANK | Oxygen |
| disease | IDO | intervention |
| disease | MESH | influenza |
| drug | DRUGBANK | Creatinine |
| disease | IDO | history |
| disease | MESH | cirrhosis |
| disease | MESH | ascites |
| disease | MESH | bleeding |
| disease | MESH | hepatic encephalopathy |
| disease | MESH | abnormalities |
| disease | MESH | Gilbert’s syndrome |
Original Article
(Visited 1 times, 1 visits today)